Lexaria Bioscience Corp. — Director's Dealing 2022

Oct 19, 2022

SEC Form 4/A — Form 4/A

Issuer: Lexaria Bioscience Corp. (LEXX)
CIK: 0001348362
Period of Report: 2022-10-12

Reporting Person: BUNKA CHRISTOPHER (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-10-12	common shares	P	21900	$1.988	Acquired	237812	Indirect
2022-10-13	common shares	P	16600	$2.1	Acquired	254412	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
common shares	273543	Direct
common shares	215912	Indirect

Footnotes

F1: This Form 4/A is being filed to correct the transaction code for the open market purchase of common shares made by Mr. Bunka as previously notated as a grant or award in the Form 4 originally filed on 10/13/2022.